239 related articles for article (PubMed ID: 8604585)
1. Long-term therapy with deferiprone.
Olivieri NF
Acta Haematol; 1996; 95(1):37-48. PubMed ID: 8604585
[TBL] [Abstract][Full Text] [Related]
2. Orally active iron chelators in the treatment of iron overload.
Olivieri NF
Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A; Felisi M; De Sanctis V; De Mattia D
Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
[TBL] [Abstract][Full Text] [Related]
6. Long term deferiprone chelation therapy.
Hoffbrand VA; Wonke B
Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
[No Abstract] [Full Text] [Related]
7. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
8. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
[TBL] [Abstract][Full Text] [Related]
10. The controversial role of deferiprone in the treatment of thalassemia.
Richardson DR
J Lab Clin Med; 2001 May; 137(5):324-9. PubMed ID: 11329529
[TBL] [Abstract][Full Text] [Related]
11. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
[TBL] [Abstract][Full Text] [Related]
12. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
13. Deferiprone: New insight.
Piga A; Roggero S; Vinciguerra T; Sacchetti L; Gallo V; Longo F
Ann N Y Acad Sci; 2005; 1054():169-74. PubMed ID: 16339662
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone: new preparation. Poorly assessed.
Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
[TBL] [Abstract][Full Text] [Related]
15. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
16. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
17. Deferiprone approved for iron overload.
Traynor K
Am J Health Syst Pharm; 2011 Nov; 68(22):2106. PubMed ID: 22058092
[No Abstract] [Full Text] [Related]
18. An oral treatment for iron overload in thalassemia?
Kowdley KV; Tavill AS
Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
[No Abstract] [Full Text] [Related]
19. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
